GlobeNewswire

Casa Systems to Showcase Innovative Core and Access Solutions that Transform All Broadband Networks to 5G at ANGA COM 2018

Dela

ANDOVER, Mass., June 11, 2018 (GLOBE NEWSWIRE) -- Casa Systems (Nasdaq:CASA), a leading provider of converged broadband infrastructure technology solutions for mobile, cable, fixed and converged broadband networks today announced that it will demonstrate its innovative multi-service core and access network solutions at ANGA COM, June 12-14 in Cologne, Germany, in Hall 7, Stand #G11. In addition, Casa's product and solution experts will participate in panels that explore network convergence, discuss lessons learned with virtual CCAP and Remote PHY, and share new Wi-Fi use cases, coverage and user experiences.

"For any broadband network, at any stage of transformation, Casa Systems has the technology to help service providers step up their broadband network's potential," said Jerry Guo, CEO at Casa Systems. "Our portfolio of agile broadband solutions are engineered for the performance, flexibility and scale that cable, wireless, fixed and converged networks require for 5G."

Casa Demonstrations at ANGA COM 2018

In today's all connected world, service providers are transforming networks to increase capacity and improve agility. Casa Systems accelerates network innovation with a suite of intelligent broadband solutions that deliver the bandwidth and service agility that service providers need today with a clear path to a converged, virtualized and distributed multi-access network.  
                                                             
Distributed, Programmable and Agile HFC Network:  Casa's Axyom(TM) Virtual CCAP (vCCAP) and Distributed Access Architecture (DAA) solutions enable intelligent design and programmability throughout the next generation cable network, from the core to the edge.  Casa's Axyom vCCAP virtualizes CCAP core functions in a micro-services based software architecture and delivers multi-dimensional scaling and high performance from a lean vCPU footprint. Developed for the virtual compute environment from the ground up, the Axyom vCCAP is designed to support full interoperability in a distributed access architecture. Casa's Distributed Access solution helps service providers push capacity to the edge, leverage current investments and densify access networks to flexibly deliver video, voice and data while efficiently supporting bandwidth growth, ensuring customer satisfaction. Casa will demonstrate vCCAP interoperability using open standards with the BKtel Remote PHY module. 

5G Flexibility for Fixed Networks:  The latest addition to Casa's 5G converged software architecture, the Axyom(TM) Virtual Broadband Network Gateway (vBNG) Router solution is the industry's first virtualized broadband network gateway that delivers superior performance, multi-dimensional scaling, and flexibility needed to address the greater diversity of 5G broadband demands. At ANGA COM, Casa will showcase an integrated vBNG solution that demonstrates not only high capacity and performance, but also a unique ability to offload and distribute the data plane so service providers can better control and distribute intelligence to the network edge. 

Unified Broadband Services:  Casa's Unified Broadband Services solution provides a logical approach to meet capacity challenges by extending the life of existing HFC investments.  Casa will demonstrate the ability to deliver full DOCSIS 3.1 services (voice, video and data) over the traditional HFC network and Distributed Access Network from a single integrated CCAP chassis, which gives service providers the flexibility to target capacity where it is needed most while maximizing existing CCAP investments. 

Programmable Access Using CableLabs' Standard Models:  Native NETCONF protocol and standards-based YANG models from Casa Systems give service providers programmatic control over remote devices which reduces costs, complexity and time to market of DAA implementations.  With Casa's solutions, service providers can choose best of breed SDN controllers and NFV orchestrators with standardized Yang models, assuring interoperability.  Casa will demonstrate full MAC domain configuration of a Remote PHY device using NETCONF / Yang.

Visit Casa Systems and view these demos in Hall 7, Stand #G11 at ANGA COM.

Casa Experts to Discuss Fixed and Mobile Convergence, Fiber Deep Solutions and the Wi-Fi User Experience During Panels

  • Casa's John Knox, Principal Solution Architect for Cable Access, will talk about the lessons learned from Fiber Deep implementations during the "Future-Proofed Fiber: From the Headend to the Terminal" panel on Tuesday, June 12 at 03:00 in Room 2.
     
  • Casa's Michael DiGiorgio, Director of Product Management - Wi-Fi, will participate on the panel,  "Wi-Fi - Use Cases, Coverage and User Experience" on Thursday, June 14 at 11:30, Room 2. The panel will discuss how to manage the Wi-Fi experience to deliver revenue and enhance security.  
     
  • Casa's Peter Wolff, Manager, Solutions Architect Group, will talk about delivering fixed and mobile convergence solutions with a common software platform at the "SDN & NFV - Enabling Fixed and Mobile Convergence" panel on Thursday, June 14 at 01:00, Room 2. 

About Casa Systems, Inc.
Casa Systems, Inc. (Nasdaq:CASA) delivers converged broadband technology solutions that enable mobile, cable and fixed network service providers to meet the growing demand for gigabit bandwidth and services. Our suite of distributed and virtualized solutions for fixed and mobile 5G ultra-broadband networks are engineered for performance, flexibility and scale. Commercially deployed in over 70 countries, Casa serves more than 450 Tier 1 and regional service providers worldwide.

For more information, please visit us at http://www.casa-systems.com.                                                          

CONTACT INFORMATION:

Alicia Thomas
Casa Systems, Inc.
100 Old River Road
Andover, Mass. 01810
+1.817.909.8921
alicia.thomas@casa-systems.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Casa Systems, Inc. via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in October and November22.10.2018 16:00Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Announces Upcoming Investor Events in October and November Immunicum AB (publ; IMMU.ST) announced today that the Company will participate in and host investor events in October and November. At all events Carlos de Sousa, CEO of Immunicum, and other members of the management team, will provide a corporate presentation and be available for a question and answer session. BioStock Life Science Summit Date: October 25, 2018 Presentation Time: 18.50 Central European Time Venue: Medicon Village, Scheelevägen 2, Building 302-auditorium, Lund, Sweden Registration Link: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicum Investor Event - Gothenburg Date: October 29, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venue: First Hotel G, Nils Ericsonplatsen, 411 03 Gothenburg, Sweden Immunicum Investor Event - Stockholm Date: October 30, 2018 Presentation Time: 17.30 - 20.00 Central European Time Venu

Immunicum AB (publ) meddelar kommande investerarevent under oktober och november22.10.2018 16:00Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) meddelar kommande investerarevent under oktober och november Immunicum AB (publ; IMMU.ST) meddelar i dag att bolaget kommer att anordna och delta i investerarträffar under oktober och november. Vid samtliga event kommer Carlos de Sousa, Immunicums VD, och övriga medlemmar av ledningsgruppen, att hålla en presentation av bolaget och vara tillgängliga för att svara på frågor. BioStock Life Science Summit Datum: 25 oktober 2018 Presentationstid: Kl. 18.50 CET Plats: Medicon Village, Scheelevägen 2, byggnad 302 - hörsalen, Lund Länk för registrering: https://www.eventbrite.com/e/biostock-life-science-summit-tickets-51114333347 Immunicums investerarevent - Göteborg Datum: 29 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: First Hotel G, Nils Ericsonplatsen, 411 03, Göteborg Immunicums investerarevent - Stockholm Datum: 30 oktober 2018 Presentationstid: Kl. 17.30 - 20.00 CET Plats: Ingenjörshuset Citykonferensen, Plan 1, Malmski

Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress22.10.2018 12:45Pressmeddelande

Pressmeddelande 22 oktober 2018 Immunicum AB (publ) presenterar prekliniska resultat för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress -- Intratumoral behandling med ilixadencel, en cellbaserad, lagringsbar immunaktiverare, ger en synergistisk antitumöreffekt och förstärker effekten av behandling med anti-PD-1 och anti-CD137 i djurmodeller -- Immunicum AB (publ; IMMU.ST) presenterar under 2018 års ESMO kongress (European Society for Medical Oncology) prekliniska resultat som visar en synergistisk anti-tumöreffekt när bolagets ledande produkt ilixadencel ges i kombination med en checkpointhämmare eller immunaktiverare. Resultaten från studien, som presenteras på en poster, visar att intratumoralt administrerat ilixadencel kan förstärka anti-tumörsvar och överlevnad vid behandling med checkpointhämmare eller immunaktiverare. Detta visar på potentialen hos ilixadencel att bli en komplementerande verkningsmekanism till flera olika framtida im

Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 201822.10.2018 12:45Pressmeddelande

Press Release 22 October 2018 Immunicum AB (publ) Presents Preclinical Results of Ilixadencel in Combination with Checkpoint Inhibitors and Immune Enhancers at ESMO 2018 -- Intratumoral treatment with ilixadencel, an off-the-shelf cell-based immune primer, provides synergistic anti-tumor effect and enhances efficacy of anti-PD-1 and anti-CD137 treatment in animal model -- Immunicum AB (publ; IMMU.ST) announced today the presentation of preclinical results that showed anti-tumor synergy between its lead product ilixadencel and a checkpoint inhibitor or an immune enhancer in a poster at the European Society for Medical Oncology (ESMO) 2018 Congress. The results of the study highlight the ability of intratumoral ilixadencel to enhance anti-tumor response and survival of systemic checkpoint inhibitors (anti-PD-1) or immune enhancers (anti-CD137/4-1BB). This emphasizes the potential for ilixadencel in multiple future immuno-oncology combination strategies by incorporating complementary mech

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

Karolinska Development's portfolio company OssDsign announces FDA clearance for Cranioplug22.10.2018 09:00Pressmeddelande

STOCKHOLM, October 22, 2018. Karolinska Development's portfolio company OssDsign announces that its latest product Cranioplug has received 510(k) clearance by the FDA, which allows marketing and sales of the product in US. The implant is the first product of its kind in the US market. Cranioplug is an implant used during neurosurgical procedures. The product is intended to cover and plug holes drilled into the skull during surgery and to reattach cranial bone removed during surgery. Cranioplug resorbs and is replaced with bone during the healing process. Anders Lundqvist, CEO of OssDsign, said: "Receiving clearance for Cranioplug is an important step for OssDsign. This motivates us to increase our presence in the US market and continue to build our US organization throughout 2018 and beyond. The regenerative features of OssDsign's calcium phosphate composition are now getting recognized, and it's our mission to turn them into real benefits for patients, surgeons and hospital systems."

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum